Close Menu

siRNA

Life Technologies, Altogen Biosystems

The Phase I study is being conducted in the US and Israel with two patient subgroups — stratum I, which includes patients with chronic nerve atrophy and began dosing in March; and stratum II, which is enrolling patients with recent onset of NAION.

The siRNAs inhibited tumor necrosis factor-alpha, a pro-inflammatory cytokine implicated in a variety of inflammatory diseases, in the animals' colons and protected against ulcerative colitis, according to the paper.

The company noted that since it develops LNP formulations individually for each of its drug candidates, the delay in TKM-apoB will have "no impact" on any of its other drug programs or those of its collaboration partners, who include Roche and Pfizer.

The grants, which are focused on therapeutic applications of siRNAs, are collectively worth more than $800,000.

Earlier this summer, the company completed a phase Ia trial, finding the agent to be safe and well-tolerated in healthy volunteers.

Cellecta

The collaboration brings together Ariadne, Cellecta, and the Roswell Park Cancer Institute to develop "a better understanding of the mechanisms of prostate cancer that result in novel targets and biomarkers."

According to a company official, future deals, as with the one with Nitto Denko, will be driven by Quark's freedom to operate in the siRNA drugs space.

Last week, EGEN said it had extended a collaboration with SurModics to develop a controlled-release system for siRNA delivery. As with its other programs, the company plans to let the delivery route determine the indications it pursues.

Pages

At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.

The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.

Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.

In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.